Galectin Therapeutics Stock
GALT Stock ,Shares of the biotech in the early stages of clinical trials Galectin Therapeutics ( GALT 9.81 percent) are ripping higher this morning after the company released a patent update that covers the use of GR-MD-01 as a treatment for the pulmonary fibrous. The patent is believed to extend the duration of the drug’s exclusivity to 2032.
At the time of 12:25 p.m. EDT Galectin’s shares remain increasing by 13.3 percent in the wake of this announcement.
So , what’s next?
The reason why the stock price of Galectin’s rose but it is a specific statement within the release by Galectin’s CEO Dr. Harold H. Shlevin. He said that “Pharmaceutical companies may have an interest in this disease as there is a sizable section of the population in need of treatment and well defined regulatory pathways for approval of agents to treat pulmonary fibrosis.” In a nutshell Galectin’s CEO appears to be suggesting that a bigger partner could be looking to sign an lucrative licensing agreement right with this technology now that it has an impressive intellectual portfolio surrounding it.
What’s next?
If it is true, this particular turn of events could turn out to be an important moment for the company’s development. After the release of mixed mid-stage results for the GR-MD-02 drug as a potential cure for nonalcoholic steatohepatitis this year, Galectin has had difficulty coming up with a plan of action. In actual fact, Galectin’s leadership has been reportedly contemplating the possibility of selling Galectin due to its very poor financial standing and its apparent inability to steer an effective drug through the process of clinical trials.
The most important thing to remember is that this patent may provide vital energy to any ongoing discussions with a potential purchaser or potential licenseewhich should be good news for Galectin’s shareholders due to the company’s urgent need of new source of money.
Galectin Therapeutics Company Info
A company that is in the stage of development for pharmaceuticals involved in the research, commercialization and development of therapeutic compounds made of carbohydrates to treat advanced liver cancer, liver cancer cardiovascular, microbial and inflammatory disorders.
Galectin Therapeutics Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| GALT | -35.68% | -66.07% | -19.42% | -89% |
| S&P | -7.62% | +49.76% | +8.40% | +363% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $15.83M | -56.7% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $29.73M | +54.1% |
| Short Term Debt | $0.04M | +105.3% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -126.4% | +46.2% |
| Return On Invested Capital | -357.0% | -4.4% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$8.35M | +67.0% |
| Operating Free Cash Flow | -$8.35M | +67.0% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 17.55 | 13.65 | -9.21 | -5.55 | – |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 17.55 | 13.65 | -9.21 | -5.55 | – |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -15.44 | -9.62 | -8.85 | -13.91 | -46.7% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -152.8% | -227.7% | -566.8% | -3728.1% | +3,430.0% |
| Total Debt | $29.06M | $29.29M | $29.62M | $29.77M | +54.1% |
